On the evening of March 18, 2026, Johnson & Johnson announced that its oral peptide drug Icotrokinra (brand name: ICOTYDE) has been approved by the FDA for the treatment of moderate to severe plaque psoriasis (PsO) in adolescents aged 12 years and older and adults.
It is the world’s first and only targeted oral peptide drug that blocks the IL-23 receptor.
Icotrokinra
| Target: | IL-23R |
| Originator: | Janssen Biotech, Inc. |
| Developers: | Janssen Research & Development LLC, Janssen (China) Investment Co., Ltd., Janssen Pharmaceutica NV |
| Indications Under Development: | Plaque Psoriasis, Crohn’s Disease, Ulcerative Colitis |
| Highest R&D Phase: | Approved for Marketing |
| First Approval Date: | 2026-03-17 |
| First Approved Country/Region: | United States |
Icotrokinra Starting Materials and Intermediates
| Intermediates Name | CAS NO. |
| 2-Naphthaldehyde | 66-99-9 |
| 4-3-(Naphthalen-2-yl)-2-oxopropanoic acid | 111726-64-8 |
| trans-3-(3-Pyridyl)acrylic acid | 19337-97-4 |
| 7-Methylindole | 933-67-5 |
| DL-Penicillamine | 52-66-4 |
| L-penicillamine | 1113-41-3 |
RELYBO is committed to providing global customers with high-purity, high-quality Icotrokinra intermediates with stable supply from kilogram to ton cales, accelerating the innovation and commercialization.
For product inquiries, please contact us online. stanleyhe@relybopharma.com
Copyright @ RELYBO PHARMACHEMICAL CO., LTD All Rights Reserved.
Network Supported
leave a message
Scan to wechat :
Scan to whatsapp :
